*** Welcome to piglix ***

Oxiracetam

Oxiracetam
Oxiracetam.svg
Oxiracetam.png
Clinical data
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • US: Unscheduled
Pharmacokinetic data
Bioavailability 56-82%
Onset of action 30-90 Minutes
Biological half-life 8 hours
Excretion Renal
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard 100.164.173
Chemical and physical data
Formula C6H10N2O3
Molar mass 158.155
3D model (Jmol)
Chirality Racemic mixture
 NYesY (what is this?)  

Oxiracetam (ISF 2522) is a nootropic drug of the racetam family and very mild stimulant. Several studies suggest that the substance is safe even when high doses are consumed for a long period of time. However, the mechanism of action of the racetam drug family is still a matter of research. Oxiracetam is not approved by Food and Drug Administration for any medical use in the United States.

There has been effort put into investigating the possible use of oxiracetam as a medication to attenuate the symptoms of dementia. However, no convincing results were obtained from studies where patients suffering from Alzheimer's dementia or organic solvent abuse were given 800 mg of the drug orally twice daily.

The proven effects of the drug are limited to beneficial effects that lead to higher scores in tests for logical performance, attention, concentration, memory and spatial orientation. These tests were performed on patients with mild to moderate dementia and ADHD, and the doses were 800–2400 mg orally twice a day for one to six months. Improvement has also been seen in patients with exogenic post-concussion syndrome, organic brain syndromes and other dementias. According to V. Gallai et al, oxiracetam is more effective than piracetam for this purpose.

Research shows oxiracetam improves hippocampally-mediated learning performance by increasing membrane-bound protein kinase C (PKC). When compared to control mice, oxiracetam-treated DBA mice demonstrated a significant increase in spatial learning performance as determined by the Morris water navigation task. This increase in performance was correlated to an increase in membrane-bound PKC.

Oxiracetam acts also as a positive allosteric modulator of the AMPA receptors. The major metabolites of Oxiracetam include: beta-hydroxy-2-pyrrolidone, N-aminoacetyl-GABOB, GABOB (beta-hydroxy-GABA) and glycine. Thus its metabolic route is exactly parallel to that of piracetam, aniracetam, phenylpiracetam, and all other members of the -racetam family, and also pyroglutamic acid.


...
Wikipedia

...